Report LibraryAll Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Hepatitis C
March 15, 2021
Therapeutic strategies for chronic hepatitis C have evolved rapidly over recent years. Following the debut of Sovaldi in 2013, direct-acting
antiviral (DAA) combination regimens containing at least two modes of action (nucleotide NS5B inhibitors, NS5A inhibitors, and NS3/4A protease
inhibitors) have rapidly become the standard of care, replacing older interferon-based regimens. The drastic shift to DAA regimens is due to their
significant advances in cure rates (=95%), greatly improved tolerability profiles, and shortened treatment durations (down from 48 weeks to 8–12
weeks for most patients).
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Hepatitis C (HCV) (Antiviral)|